Results 111 to 120 of about 6,976 (185)

Supplementary Figure S1 from Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors

, 2023
Shunji Takahashi, Masato Karayama, Masato Takahashi, Junichiro Watanabe, Hironobu Minami, Noboru Yamamoto, Ichiro Kinoshita, Chia‐Chi Lin, Young‐Hyuck Im, Issei Achiwa, Emi Kamiyama, Yasuyuki Okuda, Caleb Lee, Yung‐Jue Bang   +13 more
openalex   +1 more source

Idiosyncratic Drug-Induced Liver Injury and Trastuzumab Deruxtecan in Breast Cancer: A Case Report. [PDF]

Curr Oncol
Lisanti C, Della Rossa S, Zottarelli E, Vida R, Bolzonello S, Da Ros L, Zdjelar A, Cecchin E, Perin T, Puglisi F.   +9 more
europepmc   +1 more source

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE

Alexios Matikas, Bjørn Naume, Hans Wildiers, Gabe S. Sonke, Maria Vittoria Dieci, Andreas Karakatsanis, Anne Andersson, Elin Barnekow, Luisa Edman Kessler, Zakaria Einbeigi, Fredrika Killander, Barbro Linderholm, Aglaia Schiza, Antonios Valachis, Andreas Nearchou, Olav Engebraaten, Alina Carmen Porojnicu, Mari Hiorth Soland, Bård Mannsåker, Sunil Xavier Raj, Egil Støre Blix, Cecilie Soma Nordstrand, Matteo Lambertini, Claudio Vernieri, Kevin Punie, Christos Sotiriou, Jonas Bergh, Guillermo Villacampa, Athanasios Zouzos, Mats Hellström, Johan Hartman, Theodoros Foukakis   +31 more
openalex   +1 more source

Successful treatment of gynecologic malignancy with trastuzumab deruxtecan in three patients with <i>HER2</i> mutations. [PDF]

Gynecol Oncol Rep
Choudhury DS, Kurnit KC, Yamada SD, Lee NK, Vemuri A, Barroeta JE, Rayani S, Straus CM, Fleming GF, Kim JS.   +9 more
europepmc   +1 more source

Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding. [PDF]

Cancer Discov
Chen W, Gupta A, Mai N, Nag S, Lau JS, Singh S, Chodera JD, Liu B, de Stanchina E, Pareja F, Hashmi AA, Lieberman MM, Modi S, Bromberg J, Razavi P, Drago JZ, Chandarlapaty S.   +16 more
europepmc   +1 more source

Trastuzumab-Deruxtecan for the Treatment of Metastatic Breast Cancer Patients: Data from Real World Studies. [PDF]

Cancers (Basel)
Quaquarini E, Luelli F, Lasagna A, Rizzo G, Perrone L, Figini S, Achille R, Pedrazzoli P.   +7 more
europepmc   +1 more source

Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy [PDF]

Luca Scafuri, Carlo Buonerba, Vincenzo Di Lauro, Vincenzo Tortora, Marco Cascella, Luigi Liguori, Antonella Sciarra, Francesco Sabbatino, Anna Diana, Antonio Marra, Paolo Tarantino, Dario Trapani, Mario Giuliano, Grazia Arpino, Giuseppe Curigliano, Giuseppe Di Lorenzo   +15 more
openalex   +1 more source

P111 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)

, 2023
N. Harbeck, J.-F. Boileau, S. Modi, C. Kelly, S. Ohno, J. Wu, A. Konpa, P. Herbolsheimer, S. Safdar, Y. Zhang, L. Pusztai   +10 more
openalex   +1 more source

Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer. [PDF]

Curr Oncol
Vida R, Bartoletti M, Lerda L, Corsetti S, Scalone S, Calabrò A, Caroli A, Rizzetto M, Zapelloni G, Caccin E, Fucina S, Bortolin G, Cecco S, Baldo P, Pignata S, Califano D, Canzonieri V, Ditto A, Puglisi F.   +18 more
europepmc   +1 more source

Erratum to ‘Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis’ [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399]

I. Krop, Y. Cheng, J. Cortés, C. Taitt, D.-W. Kim, Chong Bai, J.F. Gruden, H.S. Rugo, V. Petry, F.-C. Cheng, S. Modi, E.F. Smit, P.A. Jänne, H. Iwata, E. Tokunaga, Y. Goto, K. Shitara   +16 more
openalex   +1 more source